Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FD0B
|
||||
| Former ID |
DIB014035
|
||||
| Drug Name |
PSN-9301
|
||||
| Synonyms |
P93/01; DPP-IV inhibitor (type 2 diabetes), Probiodrug; Dipeptidyl peptidase IV inhibitor (type 2 diabetes), (OSI) Prosidion; DPP-IV inhibitor (type 2 diabetes), (OSI) Prosidion
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Discontinued in Phase 2 | [1] | ||
| Company |
OSI Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019065) | ||||
| REF 2 | Navigating the chemical space of dipeptidyl peptidase-4 inhibitors. Drug Des Devel Ther. 2015; 9: 4515-4549. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.